How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
In this article:
Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.
Advertisement
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.